RBCC Maps Out Strategy to Curb Addiction in Canada’s Indigenous Communities

has begun working on a way to increase use of the anti-addiction drug
Naltrexone as well as to expand access to treatment in Canada’s First
Nations, Inuit and Métis indigenous populations, where addiction is
becoming a serious health problem.

According to the Canadian Centre on Substance Abuse (CCSA), the nation’s
indigenous communities are
suffering a larger percentage of
addiction to alcohol and opioids
than the rest of the country. Surveys of the First Nations, Inuit and
Métis have found people in those groups believe addiction and substance
abuse to be the top challenge facing their communities (82.6 percent of
all respondents) – greater even than housing (70.7 percent) and
employment (65.9 percent).

Responding to the rising addiction rates, the Canadian government has
instituted a National
Framework for Action
. The plan calls for Ottawa to work closely with
indigenous groups such as the National
Native Addictions Partnership Foundation
 (NNAPF) and Health Canada’s
First Nations and Inuit Health Branch (FNIHB) to develop “meaningful,
holistic and culturally appropriate solutions in the areas of access,
prevention, health promotion, treatment and aftercare,” according to

“RBCC is committed to working with the Canadian government, the CCSA and
indigenous groups to halt this crisis,” said RBCC CEO Kimberly Palmer.
“We embrace the First
Do No Harm: Responding to Canada’s Prescription Drug Crisis
It’s a great first step, but more needs to be done. So we’re working
hard to
ensure Canadian clinics have access
to a durable, long-lasting
Naltrexone protocol, such as the one being researched by RBCC. And we
continue to explore low-cost
addiction treatment

For more information on RBCC’s initiatives, please visit www.rainbowbiosciences.com.

About Rainbow Biosciences

Biosciences, LLC
, is a wholly owned subsidiary of Rainbow Coral
Corp. (RBCC).
The Company continually seeks out new partnerships with biotechnology
developers to deliver profitable new medical technologies and
innovations. For more information on our growth-oriented business
initiatives, please visit www.RainbowBioSciences.com.
For investment information and performance data on the Company, please
visit www.RainbowBioSciences.com/investors.html.

Notice Regarding Forward-Looking Statements

Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995: This news release contains forward-looking information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, including statements that include the words “believes,”
“expects,” “anticipate” or similar expressions. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, performance or achievements
of the Company to differ materially from those expressed or implied by
such forward-looking statements. In addition, description of anyone’s
past success, either financial or strategic, is no guarantee of future
success. This news release speaks as of the date first set forth above
and the Company assumes no responsibility to update the information
included herein for events occurring after the date hereof.


Rainbow Coral Corp.
Kimberly Palmer, 702-940-2345
and CEO